885521-22-2

Basic information

• Product Name: 3-IODO-4-NITRO (1H)INDAZOLE
• Synonyms: 3-IODO-4-NITRO (1H)INDAZOLE;3-Iodo-4-nitro-1H-indazol...;3-iodo-4-nitro-2H-indazole
• CAS NO: 885521-22-2
• Molecular Formula: C₇H₄IN₃O₂
• Molecular Weight: 289.03
• Mol File: 885521-22-2.mol

Chemical Properties

• Melting Point: 210-212°
• Boiling Point: 458.0±25.0 °C(Predicted)
• Appearance: /
• Density: 2.240±0.06 g/cm3(Predicted)
• Refractive Index: 1.818
• PKA: 9.12±0.40(Predicted)
• CAS DataBase Reference: 3-IODO-4-NITRO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IODO-4-NITRO (1H)INDAZOLE(885521-22-2)
• EPA Substance Registry System: 3-IODO-4-NITRO (1H)INDAZOLE(885521-22-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 885521-22-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-IODO-4-NITRO (1H)INDAZOLE is used as a building block or intermediate for the synthesis of various pharmaceuticals. Its unique structural properties and versatile reactivity make it a valuable component in the development of new drugs and materials in the field of medicinal chemistry.
Used in Antimicrobial Applications:
3-IODO-4-NITRO (1H)INDAZOLE is used as an antimicrobial agent for its potential to inhibit specific biological pathways and processes, making it a promising candidate for the development of new antimicrobial drugs.
Used in Antitumor Applications:
3-IODO-4-NITRO (1H)INDAZOLE is used as an antitumor agent due to its ability to inhibit specific biological pathways and processes, showing potential in the development of new cancer treatments.
Used in Research and Laboratory Settings:
3-IODO-4-NITRO (1H)INDAZOLE is used as a research compound in various laboratory settings for the study of its potential applications and properties, including its antimicrobial and antitumor capabilities. Its unique structural properties and versatile reactivity make it a valuable tool for the development of new drugs and materials in the field of chemical biology.

InChI:InChI=1/C7H4IN3O2/c8-7-6-4(9-10-7)2-1-3-5(6)11(12)13/h1-3H,(H,9,10)

Upstream product

• 2942-40-7 nitro-4 indazole 

Downstream Products

• 945397-06-8 3-iodo-1-[(4-methoxyphenyl)methyl]-4-nitro-indazole 
• 945396-63-4 N-(3,5-dimorpholin-4-ylphenyl)-N'-methyl-N'-(3-methyl-1H-indazol-4-yl)pyrimidine-2,4-diamine 
• 945397-07-9 1-[(4-methoxyphenyl)methyl]-3-methyl-4-nitro-indazole 
• 945397-08-0 1-[(4-methoxyphenyl)methyl]-3-methylindazol-4-amine 
• 945397-09-1 1-[(4-methoxyphenyl)methyl]-3-methyl-N-(2-methylsulfanylpyrimidin-4-yl)indazol-4-amine 
• 945397-10-4 1-[(4-methoxyphenyl)methyl]-N,3-dimethyl-N-(2-methylsulfanylpyrimidin-4-yl)indazol-4-amine 
• 945397-11-5 1-[(4-methoxyphenyl)methyl]-N,3-dimethyl-N-(2-methylsulfonylpyrimidin-4-yl)indazol-4-amine 
• 945397-12-6 N-(3,5-dimorpholin-4-ylphenyl)-N'-[1-[(4-methoxyphenyl)methyl]-3-methyl-indazol-4-yl]-N'-methyl-pyrimidine-2,4-diamine 
• 1313409-03-8 1-benzyl-3-iodo-4-nitro-1H-indazole 
• 1383475-08-8 3-iodo-4-nitro-1-(3-(trifluoromethyl)benzyl)-1H-indazole 
• 1383475-02-2 methyl 3-((3-iodo-4-nitro-1H-indazol-1-yl)methyl)benzoate 
• 945397-03-5 3-methyl-4-nitro-1H-indazole 
• 1383475-05-5 3-((3-iodo-4-nitro-1H-indazol-1-yl)methyl)-N_.N-dimethylbenzamide 
• 1383472-20-5 N-(1-benzyl-3-methyl-1H-indazol-4-yl)-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal

PYRIMIDINE DERIVATIVES

The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT6 antagonists

As part of our efforts to develop agents for cognitive enhancement, we have been focused on the 5-HT6 receptor in order to identify potent and selective ligands for this purpose. Herein we report the identification of a novel series of 3-sulfonylindazole derivatives with acyclic amino side chains as potent and selective 5-HT6 antagonists. The synthesis and detailed SAR of this class of compounds are reported.

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.